ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company reported a 12% revenue increase and improved net loss, indicating positive financial performance. However, the presence of significant risks, including regulatory and financial uncertainties, and the lack of clear management responses in the Q&A session temper optimism. The market cap suggests moderate sensitivity to these factors, leading to a neutral stock price prediction.
Key Financial Performance
Revenue The company reported revenue of $45 million for the fiscal year 2025, which represents a 12% increase year-over-year. This growth was attributed to higher sales of its oncology products and increased adoption of its immunotherapy treatments.
Operating Expenses Operating expenses for the year were $120 million, up 8% compared to the previous year. The increase was primarily due to expanded clinical trial activities and investments in manufacturing capabilities.
Net Loss The net loss for the fiscal year 2025 was $75 million, a 5% improvement from the previous year. This improvement was driven by higher revenues and cost management initiatives.
Cash Flow The company reported a negative cash flow of $30 million for the year, which was a 10% improvement year-over-year. This was due to better working capital management and reduced capital expenditures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The presentation contains forward-looking statements that involve risks and uncertainties, which could cause actual results to differ materially from expectations. This includes risks related to financial performance, expected revenues, operating expenses, cash runway, clinical development plans, regulatory submissions and approvals, strategic collaborations, manufacturing capabilities, commercial launch planning, market opportunities, and business strategy.
Regulatory risks: The company acknowledges risks related to regulatory submissions and approvals, which could impact clinical development plans and commercial launch timing.
Financial risks: There are risks associated with the company's financial performance, including expected revenues, operating expenses, and cash runway, which could affect its ability to execute strategic objectives.
Strategic execution risks: Challenges in strategic collaborations, manufacturing capabilities, and commercial launch planning could adversely impact the company's market opportunities and business strategy.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Collaborations: Statements regarding strategic collaborations and their future implications.
Manufacturing Capabilities: Statements about future manufacturing capabilities and plans.
Commercial Launch Planning and Timing: Statements about future commercial launch planning and timing.
Market Opportunities: Statements about future market opportunities.
Business Strategy: Statements about future business strategy.
Future Financial Performance: Statements regarding future financial performance.
Expected Revenues: Statements about expected future revenues.
Operating Expenses: Statements about future operating expenses.
Cash Runway: Statements about future cash runway.
Clinical Development Plans: Statements about future clinical development plans.
Regulatory Submissions and Approvals: Statements about future regulatory submissions and approvals.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Andres Maldonado
BTIG LLC
Boral Capital
CEO Director
Capital LLC
Chairman Global
Chief Executive
Chief Scientific
Co LLC
Co Research
Director Edward
Division Andres
Division Jason
Division Jeet
Division PM
Division Yuxi
Dong
Executive Chairman
Founder Executive
Global Chief
LLC Research
Medical Officer
Officer President
Patrick Soon
Research Division
Scientific Medical
Shiong Founder
Soon Shiong
IBRX Transcript
ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript
Unknown3-3
The company reported a 12% revenue increase and improved net loss, indicating positive financial performance. However, the presence of significant risks, including regulatory and financial uncertainties, and the lack of clear management responses in the Q&A session temper optimism. The market cap suggests moderate sensitivity to these factors, leading to a neutral stock price prediction.
ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-16
IBRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
